Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf264 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, 2025. Verfasst von Jun Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University o…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Perioperative Care, Carcinoma, Small Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Province Clinical Key Specialty Construction.
Abstract (Originalsprache)
Background
The optimal treatment strategy for limited-stage small cell esophageal carcinoma (LS-SCEC) remains uncertain. This study aimed to retrospectively evaluate the efficacy of perioperative therapy in these patients. Materials and Methods Between June 2005 and November 2022, 156 patients with LS-SCEC who underwent esophagectomy were included in this study. The primary endpoint was overall survival (OS), and secondary endpoints included disease-free survival (DFS) and postoperative complications. Prognostic factors were analyzed using univariate and multivariate Cox regression models, as well as propensity score matching.
Results
Of the 156 patients, 33 (21.2%) patients received neoadjuvant chemotherapy, 76 (48.7%) underwent adjuvant chemotherapy, and 13 (8.3%) received adjuvant chemoradiotherapy. Post-surgery, 33 (21.2%) patients were classified as stage I, 40 (25.6%) as stage II, 61 (39.1%) as stage III, and 22 (14.1%) as stage IV. The median OS was 21.0 months, with 5-year OS and DFS rates of 25.9% and 21.9%, respectively. Multivariate analysis identified clinical T stage (P = .049), neural invasion (P = .002), N stage (P = .006), and adjuvant therapy (P = .001) as independent prognostic factors. Neoadjuvant chemotherapy significantly improved OS, with a 5-year OS rate of 37.7% compared to 0.0% in the non-neoadjuvant chemotherapy group (P < .001). Across the cohort, adjuvant therapy enhanced both OS and DFS.
Conclusions
Perioperative therapy is crucial for LS-SCEC management. Neoadjuvant chemotherapy improves OS in patients with LS-SCEC. Adjuvant chemotherapy is recommended almost for all patients with LS-SCEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, China.
- Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, Chi…
- Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic…
ORCID-Profile: Xiang Zhuang
Förderung
- Sichuan Province Clinical Key Specialty Construction
Zitieren
APA
Peng, J., Chen, J. F., Wang, Y., Zhu, J., He, J. T., Lai, Q., Leng, X. F., Huang, Y. Z., & Zhuang, X. (2025). Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf264
Vancouver
Peng J, Chen JF, Wang Y, Zhu J, He JT, Lai Q, et al. Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf264
BibTeX
@article{Peng2025,
author = {Peng, Jun and Chen, Jin-Feng and Wang, Yi and Zhu, Jiang and He, Jin-Tao and Lai, Qi and Leng, Xue-Feng and Huang, Ying-Zhao and Zhuang, Xiang},
title = {Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf264}
}
EUVIMED